Virtus ETF Advisers LLC Buys New Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Virtus ETF Advisers LLC bought a new stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 7,247 shares of the biotechnology company’s stock, valued at approximately $65,000.

Several other large investors have also recently added to or reduced their stakes in ATXS. KLP Kapitalforvaltning AS acquired a new stake in Astria Therapeutics in the 4th quarter valued at approximately $41,000. Tower Research Capital LLC TRC increased its position in Astria Therapeutics by 109.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 2,766 shares during the period. Teacher Retirement System of Texas acquired a new stake in Astria Therapeutics in the 4th quarter valued at approximately $91,000. New York State Common Retirement Fund increased its position in Astria Therapeutics by 67.0% in the 4th quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 4,300 shares during the period. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Astria Therapeutics in the 4th quarter valued at approximately $107,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Wedbush reaffirmed an “outperform” rating and set a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Cantor Fitzgerald assumed coverage on Astria Therapeutics in a research note on Monday. They set an “overweight” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Finally, JMP Securities assumed coverage on Astria Therapeutics in a research note on Friday, January 31st. They set an “outperform” rating and a $26.00 price target for the company. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Astria Therapeutics currently has an average rating of “Buy” and an average target price of $26.60.

Astria Therapeutics Stock Down 4.1 %

ATXS opened at $4.96 on Tuesday. The firm has a market cap of $279.91 million, a PE ratio of -2.37 and a beta of 0.68. The business has a fifty day simple moving average of $5.52 and a 200-day simple moving average of $8.03. Astria Therapeutics, Inc. has a fifty-two week low of $3.56 and a fifty-two week high of $12.92.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.01. On average, equities research analysts anticipate that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.